Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression

Behavioural Brain Research

Volumn 238, Issue 1, 2013, Pages 48-52

  Koike, Hiroyuki ^a   Fukumoto, Kenichi ^a   Iijima, Michihiko ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

BDNF; MGlu2 3 receptor antagonist; Novelty suppressed feeding test; Tail suspension test; TrkB

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; K 252A; KETAMINE; METABOTROPIC RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; EXPERIMENTAL TEST; MALE; MOUSE; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST;

AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; RECEPTOR, TRKB; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION; XANTHENES;

EID: 84868559249     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.10.023     Document Type: Article

References (47)

1. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47:351-354.
2. Zarate C.A, Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.
3. Machado-Vieira R., Yuan P., Brutsche N., DiazGranados N., Luckenbaugh D., Manji H.K., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. Journal of Clinical Psychiatry 2009, 70:1662-1666.
4. Mathew S.J., Murrough J.W. aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology 2010, 13:71-82.
5. Duncan W.C., Sarasso S., Ferrarelli F., Selter J., Riedner B.A., Hejazi N.S., et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. International Journal of Neuropsychopharmacology 2012, http://dx.doi.org/10.1017/S1461145712000545.
6. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 2010, 67:793-802.
7. Green S.M., Coté C.J. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Annals of Emergency Medicine 2009, 54:181-190.
8. Maeng S., Zarate C.A, Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 2008, 63:349-352.
9. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behavioural Brain Research 2011, 224:107-111.
10. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
11. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biological Psychiatry 2011, 69:754-761.
12. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
13. Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biological Psychiatry 2012, 71:996-1005.
14. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34:1-26.
15. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS & Neurological Disorders - Drug Targets 2007, 6:87-100.
16. Wierońska J.M., Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochemistry International 2009, 55:85-97.
17. Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A. mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology. in press.
18. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
19. Karasawa J., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Research 2005, 1042:92-98.
20. Yoshimizu T., Shimazaki T., Ito A., Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology 2006, 186:587-593.
21. Pałucha-Poniewiera A., Wierońska J.M., Brański P., Stachowicz K., Chaki S., Pilc A. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology 2010, 212:523-535.
22. Koike H., Iijima M., Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 2011, 61:1419-1423.
23. Dwyer J.M., Lepack A.E. Duman RS. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. International Journal of Neuropsychopharmacology 2012, 15:429-434.
24. Yamada N., Katsuura G., Ochi Y., Ebihara K., Kusakabe T., Hosoda K., et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 2011, 152:2634-2643.
25. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neuroscience and Biobehavioral Reviews 2005, 29:571-625.
26. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
27. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
28. Xi Z.X., Baker D.A., Shen H., Carson D.S., Kalivas P.W. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 2002, 300:162-171.
29. Melendez R.I., Kalivas P.W. Metabotropic glutamate receptor regulation of extracellular glutamate levels in the prefrontal cortex. Annals of the New York Academy of Sciences 2003, 1003:443-444.
30. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 1997, 17:2921-2927.
31. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
32. Jourdi H., Hsu Y.T., Zhou M., Qin Q., Bi X., Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. Journal of Neuroscience 2009, 29:8688-8697.
33. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience 2002, 22:3251-3261.
34. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Research 2005, 1037:204-208.
35. Naumenko V.S., Kondaurova E.M., Bazovkina D.V., Tsybko A.S., Tikhonova M.A., Kulikov A.V., et al. Effect of brain-derived neurotrophic factor on behavior and key members of the brain serotonin system in genetically predisposed to behavioral disorders mouse strains. Neuroscience 2012, 214:59-67.
36. Cunha C., Brambilla R., Thomas K.L. A simple role for BDNF in learning and memory. Frontiers in Molecular Neuroscience 2010, 3:1-14.
37. Ornstein P.L., Bleisch T.J., Arnold M.B., Kennedy J.H., Wright R.A., Johnson B.G., et al. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. Journal of Medicinal Chemistry 1998, 41:358-368.
38. Voleti B., Duman R.S. The roles of neurotrophic factor and Wnt signaling in depression. Clinical Pharmacology and Therapeutics 2012, 91:333-338.
39. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008, 15(64):527-532.
40. Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Research. Molecular Brain Research 2005, 136:29-37.
41. Hsiung S.C., Adlersberg M., Arango V., Mann J.J., Tamir H. Liu KP. Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. Journal of Neurochemistry 2003, 87:182-194.
42. Jernigan C.S., Goswami D.B., Austin M.C., Iyo A.H., Chandran A., Stockmeier C.A., et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:1774-1779.
43. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. Biological Psychiatry 2010, 67:1017-1025.
44. Laje G., Lally N., Mathews D., Brutsche N., Chemerinski A., Akula N., et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biological Psychiatry 2012, http://dx.doi.org/10.1016/j.biopsych.2012.05.031.
45. Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., et al. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 1998, 37:1-12.
46. Witkin J.M., Monn J., Brittion T., Ornstein P., Li X., Johnson B.G., et al. Further evidence for a metabotropic glutamate group II antagonist mechanism for the induction of antidepressant-like effects in rodents. Neuropsychopharmacology 2006, 31:S166.
47. Mitsukawa K., Mombereau C., Lötscher E., Uzunov D.P., Van Der Putten H., Flor P.J., et al. Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology 2006, 31:1112-1122.